|
Overall Morningstar
Rating™ |
| What is this? |
 |
 |
| As of 2009-10-31 |
|
Out of
Health Funds |
|
| Rating derived from a weighted average of the fund's 3, 5, 10-year rating which are based on risk-adjusted performance. |
|
|
|
Morningstar®
Style Box™ |
| What is this? |
|
 |
|
Large |
|
|
Growth |
|
|
|
|
|
|
|
|
| As of
2009-09-30 |
|
|
| Day Change |
| $ -0.01 |
|
|
| NAV (2009-11-10) |
| $ 8.77 |
|
|
| YTD Return % (2009-11-10) |
| 7.48% |
|
|
| Total Assets ($ mil) |
| 1,126 |
|
| Growth of $10,000 |
 |
Fund: |
Eaton Vance Worldwide Health Sci A |
| (from
1999-01-01
to 2009-10-31) |
 |
Category: |
Health |
|
 |
Index: |
S&P 500 TR |
| Total Annualized Returns % |
1yr, 3yr and 5yr Returns as of 2009-11-10 |
| Inception date: 1985-07-26 |
10yr and Inception Returns as of 2009-10-31 |
|
YTD Returns as of 2009-11-10 |
|
|
YTD |
1 Year |
3 Year |
5 Year |
10 Year |
Since Inception |
| Fund |
5.02 |
24.10 |
0.76 |
3.70 |
8.07 |
13.14 |
| +/- Category |
-5.03 |
15.35 |
3.38 |
0.56 |
2.21 |
--- |
| +/- S&P 500 TR |
-18.50 |
-24.70 |
6.66 |
3.02 |
--- |
--- |
|
|
| Standardized Annual Returns % more on standardized returns |
| Quarter-End (as of
2009-09-30) |
3.03 |
-5.53 |
1.42 |
3.04 |
8.59 |
13.21 |
| Month-End (as of 2009-10-31) |
-3.44 |
-0.56 |
-2.05 |
2.22 |
7.43 |
12.86 |
|
|
| After Tax Returns % (as of
2009-09-30
)
|
| On Distribution |
--- |
-3.24 |
-3.72 |
1.17 |
6.64 |
--- |
| On Distribution & Sale of Shares |
--- |
1.79 |
-1.88 |
1.80 |
6.41 |
--- |
|
|
| Morningstar Rating |
--- |
--- |
 |
|
 |
--- |
|
| # of compared funds covered (3 yrs : out of 151 funds), (5 yrs : out of 143 funds), (10 yrs : out of 60 funds). Ratings are based on risk-adjusted performance. The maximum initial sales fee is
5.75%,
the maximum deferred sales fee is
none,
and the maximum redemption sales fee is
1.00%.
|
|
| The performance quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate thus an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted herein. |
|
|
|
|
| Sector Breakdown % |
|
 |
Information |
0.00 |
 |
Software |
0.00 |
 |
Hardware |
0.00 |
 |
Media |
0.00 |
 |
Telecommunications |
0.00 |
|
|
|
 |
Service |
100.00 |
 |
Healthcare |
100.00 |
 |
Consumer Services |
0.00 |
 |
Business Services |
0.00 |
 |
Financial Services |
0.00 |
|
|
|
 |
Manufacturing |
0.00 |
 |
Consumer Goods |
0.00 |
 |
Industrial Materials |
0.00 |
 |
Energy |
0.00 |
 |
Utilities |
0.00 |
|
|
|
|
| |
|
|
| Asset Allocation |
|
 |
|
| % of Net Assets |
 |
Cash |
1.8 |
 |
Stocks |
96.4 |
|
Bonds |
0.0 |
 |
Other |
1.8 |
|
|
|
Foreign Stocks |
30.1 |
|
(as a % of Assets) |
|
|
| Data through 2009-09-30 |
Data through 2009-09-30 |
 |
| Holding Status |
|
| Total Number of Stock Holdings |
41 |
|
Turnover % |
54 |
| Total Number of Bond Holdings |
0 |
|
30 Day SEC Yield % |
0.00 |
| % of Assets in Top 10 Holdings |
38.40 |
|
ending as of
2009-09-30 |
|
|
|
|
View Data Definitions |
| Top 10 Holdings |
Sector |
P/E |
YTD
Return % |
% of Net
Assets |
|
|
|
|
|
|
|
Johnson & Johnson |
|
13.09 |
7.37 |
5.15 |
|
Roche Holding AG |
|
31.75 |
6.86 |
4.44 |
 |
Genzyme Corporation |
|
44.25 |
-24.59 |
4.12 |
|
Gilead Sciences, Inc. |
|
24.33 |
-9.29 |
3.74 |
|
Vertex Pharmaceuticals |
|
--- |
26.86 |
3.68 |
|
 |
|
Shire PLC ADR |
|
46.95 |
26.68 |
3.68 |
|
Novartis |
|
--- |
--- |
3.59 |
|
Amgen, Inc. |
|
14.81 |
-4.10 |
3.52 |
 |
Endo Pharmaceutical Holdings, Inc. |
|
12.21 |
-14.18 |
3.33 |
|
Baxter International Inc. |
|
16.95 |
2.84 |
3.15 |
|
|
 |
Data through 2009-09-30 |
|
| YTD Return through 2009-11-20 |
|
|
| Fund Inception: 1985-07-26 |
|
Portfolio Manager (Start Date) |
|
|
|
|
|
Samuel D. Isaly (1985-07-26) |
|
|
|
Isaly is a portfolio manager with OrbiMed Advisors. Previously, he was a president and partner with Mehta and Isaly Asset Management. From 1986 to 1989, he was a senior vice president with S.G. Warburg & Company. He also spent more than three years as a partner with Gramercy Associates, one and a half years as a vice president with Merrill Lynch & Company, and two years as a vice president with Chase Manhattan Bank. |
|
|
|
|
|
Sven Borho (2005-01-03) |
|
|
|
Sven H. Borho, CFA, is a founding General Partner of OrbiMed. Mr. Borho is a portfolio manager for OrbiMed’s public equity funds and he heads the firm’s trading efforts. He started his career in 1991 when he joined Mehta and Isaly as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. In 1993, Mr. Borho became portfolio manager to investment funds under management. Mr. Borho studied business administration at Bayreuth University in Germany and received a M. Sc. (Econ.) from The London School of Economics; he is a citizen of both Germany and Sweden. |
|
|
|
|
|
Geoffrey Hsu (2005-01-03) |
|
|
|
Hsu joined OrbiMed in 2002 as a biotechnology analyst. Prior to joining OrbiMed, he worked as a financial analyst in the healthcare investment banking group at Lehman Brothers.
Hsu has earned the right to use the Chartered Financial Analyst designation. |
|
|
|
|
|
Richard Klemm (2005-01-03) |
|
|
|
Klemm joined OrbiMed in 2000 as a biotechnology analyst.
Klemm has earned the right to use the Chartered Financial Analyst designation. |
|
|
|
|
|
Trevor Polischuk (2005-01-03) |
|
|
|
Polischuk joined OrbiMed in 2003 as an analyst covering the major global pharmaceutical industry. Previously, he worked at Lehman Brothers as a senior research analyst covering the U.S. pharmaceutical industry |
|
|
|
|
Sales Charge %
(taken from prospectus dated 2009-09-30) |
| Front: |
5.75 |
| Deferred: |
None |
|
| Expense Ratio % |
2.11 |
based on net assets
(taken from annual report dated 2009-08-31)
|
|
| Correspondence Information |
Two International Place
Boston,
MA
02110
|
|
|
|
| Telephone: |
| 800-262-1122 |
| 617-482-8260 |
|
|
